← Oncology Approval Tracker

FDA DECISION ·

Opdivo, Opdivo Qvantig and Yervoy

nivolumab (IV or with hyaluronidase-nvhy SC) + chemotherapy or IV nivolumab + ipilimumab · Bristol Myers Squibb

FDA approvalIndication revisionEsophageal squamous cell carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Restricts existing first-line therapy for adults with unresectable advanced or metastatic esophageal squamous cell carcinoma to tumors expressing PD-L1 at least 1. This applies to nivolumab plus fluoropyrimidine and platinum chemotherapy and to IV nivolumab plus ipilimumab.

LAMPGEN ANALYSIS

Why it matters

FDA revised the labeled patient population for the nivolumab-based first-line ESCC regimens after a benefit–risk reassessment.

What research teams should watch

Retain the assay result and distinguish eligible IV regimens from the subcutaneous formulation, which is not labeled for concurrent use with ipilimumab.

PRIMARY RECORDS

Sources